Fresenius Kabi’s glucagon emergency kit is a cost-effective alternative to branded kit products.
A new FDA-approved emergency kit for the treatment of severe hypoglycemic episodes in individuals with diabetes is now available, according to an announcement by Fresenius Kabi.
The Glucagon Emergency Kit includes glucagon for injection 1 mg and a prefilled glass syringe with 1 ml of sterile water for injection, USP. Glucagon for injection is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
According to Fresenius, the new kit represents a cost-effective alternative to currently marketed branded kit products, with a co-pay assistance program available to patients who qualify.
Designed for convenient and easy use, the glucagon emergency kit comes in a bright orange case, which makes it easy to identify and act quickly in the event of severe hypoglycemia.
“For people with diabetes, a severe hypoglycemic episode can occur anywhere and at any time,” John Ducker, president and CEO of Fresenius Kabi USA, said in a statement. “Our new Glucagon Emergency Kit allows clinicians flexibility and choice for treating patients experiencing severe hypoglycemia. This is another example of Fresenius Kabi’s commitment to providing cost-effective products that deliver life-saving care.”
Injection training kits will also be available to health care providers to help educate patients, Fresenius said.
GLP-1s May Protect Against Cardiovascular Outcomes Regardless of Diabetes Status
October 1st 2024Research presented at the Heart Failure Society of America 2024 Annual Meeting demonstrated that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduced cardiovascular events in patients without diabetes.